VEEA INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VEEA INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $141.8K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $9.07M | Apr 15, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $152.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $58.5K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $8.61M | Apr 15, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.66M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($47.55M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($15.64M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($338.1K) | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | $2.55M | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | ($420.0K) | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $10.58M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.59M | Apr 17, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.84M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($84.08M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($10.36M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($353.4K) | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | ($579.0K) | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | ($1.15M) | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | ($4.07M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.92M) | Apr 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $328.4K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.37M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $693.4K | Apr 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.23M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($25.60M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($12.65M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($709.6K) | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | ($431.5K) | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | ($238.6K) | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | ($1.02M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.14M) | Apr 17, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.2K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $46.2K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $35.0K | Apr 15, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.22M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $21.09M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $20.84M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $35.22M | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | $55.23M | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | $54.57M | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $324.04M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $319.73M | Apr 17, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.97M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $38.12M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $32.30M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $7.30M | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | $6.33M | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | $8.39M | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $15.43M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $21.70M | Apr 17, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.75M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($17.02M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($11.47M) | Apr 15, 2026 |
| FY2023 | Sep 30, 2023 | ($7.18M) | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | ($6.25M) | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | ($8.19M) | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | ($15.30M) | Mar 1, 2024 |
| FY2023 | Dec 31, 2021 | ($21.18M) | Mar 1, 2024 |
| FY2022 | Jan 10, 2021 | $0 | Apr 17, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.78M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $4.80M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $4.58M | Apr 15, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($224.49M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($217.83M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($170.28M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($13.50M) | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | ($13.17M) | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | ($15.72M) | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | ($15.30M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($21.18M) | Apr 17, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.69M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $6.01M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $92.7K | Mar 1, 2024 |
| FY2023 | Jun 30, 2023 | $20.9K | Mar 1, 2024 |
| FY2023 | Mar 31, 2023 | $97.8K | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $86.4K | Mar 1, 2024 |
| FY2021 | Dec 31, 2021 | $107.2K | Apr 22, 2022 |
| FY2021 | Jan 10, 2021 | $0 | Apr 22, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.80M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $23.87M | Apr 15, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.47M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 36.20M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 19.64M | Apr 15, 2025 |